Financing partner Cormark and their 4 CENT targetI wonder what is up with this company?
Why not drop coverage?
4 CENTS would seem only DAMAGING
How closely does Spectral work with such partners?
Include Mackie ( 5 CENT target ) in this discussion as well.
Cormark kept Spectral under review for 360 Days ( June 4 2015 to May 30 2016 )
When the report arrived it included details of a 3% inside ownership.
Regardless of "Insider Definition" this is a MOST misleading stat.
Toray and Birch Hill Private Equity own 40% combined
The company traded 1.2M shares for ALL of 2008
This company is held more tightly than Kermit's tooshie
Depsite waiting 360 days, the analyst failed to wait just a few more hours, as on May 31st the company held it's AGM and disclosed important details.
Neither Cormark or Mackie ever told the market about the FDA COMPASSIONATE CARE Approval
All I needed to read in the Cormark report was the detail on the toxicity of a 1970's study on polymyxin B, the anti-biotic used in the Toraymyxin ( PMX ) filter. Toraymyxin was approved for used in Japan in 1994, and has been safely used on over 180K people now. What relevance does a 1970s study in directly administered polymyxin B have?
What is really going on here?
Sqr